Bournemouth

Running trials

• Recruiting

  Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

  NCT05557695· Source

• Active, not recruiting

  Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

  NCT04305496· Phase 3· Source

• Active, not recruiting

  A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  NCT03328273· Phase 1· Source

• Active, not recruiting

  A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

  NCT02717611· Phase 2· Source

• Active, not recruiting

  Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

  NCT02477696· Phase 3· Source

• Active, not recruiting

  Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

  NCT02475681· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic lymphocytic leukaemia1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

  NCT06651970· Phase 4· Source